Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

Pharmaceuticals, Inc.

WCGPhone: 858-436-1400

Phone: 415-946-1076   CADENCE PHARMACEUTICALS, INC.CONDENSED STATEMENTS OF OPERATIONS(unaudited)(in thousands, except per share amounts)Three Months EndedMarch 31,20132012Revenue:Product revenue, net

$
23,612$
8,004Total revenues

23,6128,004Costs and expenses:Cost of product sales

8,1674,246Amortization of patent license

336336Research and development

1,3631,511Selling, general and administrative

21,63523,531Other

50-Total costs and expenses

31,55129,624Loss from operations

(7,939)(21,620)Other income (expense), net

6,576(1,053)Net loss

$
(1,363)$
(22,673)Basic and diluted net loss per share

$
(0.02)$
(0.27)Shares used to compute basic anddiluted net loss per share

85,67285,519 CADENCE PHARMACEUTICALS, INC.CONDENSED BALANCE SHEETS(in thousands)March 31,December 31,20132012(unaudited)AssetsCurrent assets:Cash, cash equivalents and short-term investments 

$
4,240$
2,072Restricted cash 

640640Accounts receivable, net 

8,9086,152Inventory 

6,0836,498Prepaid expenses and other current assets 

2,0411,154Total current assets

81,91276,516Property and equipment, net

1,9051,967Intangible assets, net

11,75412,090Other assets

907,106Total assets

$
95,661$
97,679Liabilities and Stockholders' Equity Current liabilities:Accounts payable 

$
5,808$
5,796Accrued liabilities 

12,53212,969Deferred revenue 

-2,234Current debt, less discount 

2,552-Total current liabilities

20,89220,999Other liabilities

23351Long-term debt, less discount

26,38828,818Total stockholders' equity

48,14847,811Total liabilities and stockholders' equity

$
95,661
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Ore. -- Scientists, including University of Oregon chemist ... create scaffolds of self-assembling, synthetic proteins called peptoid ... , The accomplishment -- detailed this week in ... the Proceedings of the National Academy of ... alternative design of the two-dimensional peptoid nanosheets that ...
(Date:9/2/2014)... NEW YORK , September 2, 2014 ... Market Study on Membrane Technology in Pharmaceutical, Biopharma and ... Witness Highest Growth by 2019" the global membrane technology market for ... 7,029.9 million in 2014 and is expected to grow ... to reach an estimated value of USD 10,886.0 million ...
(Date:9/2/2014)... , Sept. 2, 2014  Technology Applications International ... that its wholly-owned subsidiary Renuell Int,l, Inc. has signed ... and Space Administration ("NASA") at the Johnson Space Center ... See photos: tapplic.com/houstonphotos/ ... are very pleased to announce our latest, exclusive agreement ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Opertech ... new highly efficient, cost effective approach to sensory ... No. 8,820,265 by the U.S. Patent and Trademark ... Opertech. , “Opertech’s taste evaluation technology ... first automated high throughput system for rapid characterization ...
Breaking Biology Technology:UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2
... Therapeutics,Inc. (OTC Bulletin Board: ARNI), today announced that ... has changed from "LRRI.OB" to "ARNI.OB",effective July 17, ... Inc. is a clinical-stage biopharmaceutical company,that develops and ... Arno,s lead compound is AR-67, a novel, third-generation,camptothecin ...
... Supply Solutions(R),a focus area within SAFC(R), a ... today that the Company has launched a ... with their regulatory,requirement under the new European ... Authorization and restriction of Chemicals,(REACH) http://www.safcsupplysolutions.com/reach ...
... N.J., July 16 Johnson & Johnson Pharmaceutical,Research ... Food and Drug,Administration,s (FDA) Anti-Infective Drugs Advisory Committee ... for DORIBAX(TM) (doripenem for,injection) for the treatment of ... (VAP)., The committee voted that 500 mg ...
Cached Biology Technology:Arno Therapeutics Announces New Ticker Symbol 2SAFC Supply Solutions Launches REACH-Compliant Products and Support 2SAFC Supply Solutions Launches REACH-Compliant Products and Support 3FDA Advisory Committee Provides Opinion of DORIBAX(TM) for the Treatment of Hospital-Acquired Pneumonia 2FDA Advisory Committee Provides Opinion of DORIBAX(TM) for the Treatment of Hospital-Acquired Pneumonia 3FDA Advisory Committee Provides Opinion of DORIBAX(TM) for the Treatment of Hospital-Acquired Pneumonia 4
(Date:9/2/2014)... led by researchers at the University of Warwick in ... just published in the Journal Early Human Development ... spent in hospital after birth and the use of ... in preterm children. , Mathematic abilities are crucial for ... in very preterm children. Earlier studies of children who ...
(Date:9/2/2014)... the battle between our immune systems and cholera bacteria, ... known as phages. In a new study, researchers from ... National Public Health Laboratory, and elsewhere, report that phages ... in order to survive. Importantly, the study published ... escape from phage predation occurs during human infection. , ...
(Date:9/2/2014)... author Sam Kean stops by Reactions this week to ... shark that, despite what "Shark Week" may lead you ... at http://youtu.be/KhFygIoW_MA . , Kean,s book, "The Disappearing ... the History of the World from the Periodic Table ... a 10-episode video series produced for the newly launched ...
Breaking Biology News(10 mins):Mechanical ventilation a key indicator for pre-term children's math problems 2War between bacteria and phages benefits humans 2War between bacteria and phages benefits humans 3
... New research from The University of Western Ontario leads ... the Arctic Circle during the Pleistocene Epoch (approx. 150,000 ... three years later than modern day African elephants due ... nursing pattern could have contributed to the prehistoric elephant,s ...
... 21, 2010 Reportlinker.com announces that a new market ... Indian Biometric Market http://www.reportlinker.com/p0351944/Indian-Biometric-Market.html ... fastest emerging technology in the Indian Securities & Identification ... many conventional methods of Identity & Security checks like, ...
... Miscanthus x giganteus is the forerunner in the ... researchers believe "putting all their eggs in one basket" could ... recently reported the first natural occurrence in several decades of ... M. x giganteus is the only variety available, ...
Cached Biology News:Being good moms couldn't save the woolly mammoth 2New Miscanthus hybrid discovery in Japan could open doors for biofuel industry 2New Miscanthus hybrid discovery in Japan could open doors for biofuel industry 3
Anti-hamster Ig HRP detection kit...
The 50 ml Magnetic Separation Rack is designed to be used for small-scale separations using magnetic particles. ,Capacity: four 50 ml tubes. ,Magnets: Neodymium rare earth permanent magnets....
...
Highly efficient electroporation solution suitable for transfection of plasmid DNA, oligonucleotides and siRNA. Compatible with all common electroporators....
Biology Products: